EA201492172A1 - Биоразлагаемая композиция для доставки гидрофобных лекарственных средств - Google Patents

Биоразлагаемая композиция для доставки гидрофобных лекарственных средств

Info

Publication number
EA201492172A1
EA201492172A1 EA201492172A EA201492172A EA201492172A1 EA 201492172 A1 EA201492172 A1 EA 201492172A1 EA 201492172 A EA201492172 A EA 201492172A EA 201492172 A EA201492172 A EA 201492172A EA 201492172 A1 EA201492172 A1 EA 201492172A1
Authority
EA
Eurasian Patent Office
Prior art keywords
delivery
biological composition
polyethylene glycol
hydrophobic
active principle
Prior art date
Application number
EA201492172A
Other languages
English (en)
Other versions
EA031522B1 (ru
Inventor
Жорж Годриол
Кристоф Роберже
Original Assignee
Мединселл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49117888&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201492172(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мединселл filed Critical Мединселл
Publication of EA201492172A1 publication Critical patent/EA201492172A1/ru
Publication of EA031522B1 publication Critical patent/EA031522B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

Предложены биоразлагаемые композиции для доставки лекарственных средств, содержащие триблок-сополимер, содержащий сложный полиэфир и полиэтиленгликоль, и диблок-сополимер, содержащий сложный полиэфир и полиэтиленгликоль с блокированной концевой группой, а также по меньшей мере одно фармацевтически активное начало или гидрофобное активное начало, такое как медроксипрогестерона ацетат, левоноргестрел, циклоспорин, прогестерон или бупивакаин.
EA201492172A 2012-06-27 2013-06-27 Биоразлагаемая композиция для доставки лекарственного средства (варианты) и способ получения биоразлагаемой композиции (варианты) EA031522B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261665192P 2012-06-27 2012-06-27
PCT/IB2013/001547 WO2014001904A1 (en) 2012-06-27 2013-06-27 Biodegradable drug delivery for hydrophobic compositions

Publications (2)

Publication Number Publication Date
EA201492172A1 true EA201492172A1 (ru) 2015-09-30
EA031522B1 EA031522B1 (ru) 2019-01-31

Family

ID=49117888

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201492172A EA031522B1 (ru) 2012-06-27 2013-06-27 Биоразлагаемая композиция для доставки лекарственного средства (варианты) и способ получения биоразлагаемой композиции (варианты)

Country Status (24)

Country Link
US (5) US20150150987A1 (ru)
EP (1) EP2866837B1 (ru)
JP (1) JP6134788B2 (ru)
KR (1) KR102189442B1 (ru)
CN (1) CN104582733B (ru)
AU (1) AU2013282891B2 (ru)
BR (1) BR112014031773B1 (ru)
CA (1) CA2877083C (ru)
CL (1) CL2014003531A1 (ru)
CO (1) CO7160098A2 (ru)
CR (1) CR20140581A (ru)
CU (1) CU24287B1 (ru)
EA (1) EA031522B1 (ru)
ES (1) ES2938586T3 (ru)
HK (1) HK1208374A1 (ru)
IL (1) IL236472B (ru)
IN (1) IN2014DN11063A (ru)
MA (1) MA37809B1 (ru)
MX (1) MX353280B (ru)
SG (1) SG11201408658PA (ru)
TN (1) TN2014000520A1 (ru)
UA (1) UA113549C2 (ru)
WO (2) WO2014001904A1 (ru)
ZA (1) ZA201409291B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10251937B2 (en) 2014-01-27 2019-04-09 Medincell Retro-inverso analogs of spadin display increased antidepressant effects
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CN107072948A (zh) * 2014-09-30 2017-08-18 田纳西大学研究基金会 用于长效药物传递的原位凝胶剂
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
FR3027522B1 (fr) 2014-10-27 2016-12-09 I Ceram Composition poreuse chargee en principe actif
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
FI3377041T3 (fi) 2015-11-16 2023-11-30 Medincell S A Menetelmä farmaseuttisesti aktiivisten pääainesosien morselloimiseksi ja/tai kohdentamiseksi synoviaalikudokseen
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2018081138A1 (en) * 2016-10-24 2018-05-03 Yale University Biodegradable contraceptive implants
AU2018238136A1 (en) 2017-03-20 2019-11-07 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulations
BR112020001031A2 (pt) 2017-07-17 2020-07-14 Medincell misturas de composições de liberação de fármaco biodegradáveis para modular a cinética de liberação de fármaco de pelo menos um ingrediente ativo
CN108078911A (zh) * 2017-12-08 2018-05-29 复旦大学 用于动物避孕的热致水凝胶缓释兽药注射剂及其制备方法
AU2019325261A1 (en) * 2018-08-22 2021-03-18 Bacainn Biotherapeutics, Ltd. Cyclosporine compositions and methods of use
GB201900258D0 (en) * 2019-01-08 2019-02-27 Medincell Pharmaceutical composition
EP4027973A1 (en) 2019-09-13 2022-07-20 Medincell SA Drug delivery formulations
CN111700876A (zh) * 2020-03-12 2020-09-25 上海市肿瘤研究所 一种治疗系统性红斑狼疮的载药递送给药系统及其制备方法
US20240099964A1 (en) 2020-12-16 2024-03-28 Medincell S.A. Methods and Compositions for the Prophylactic Treatment of SARS-CoV-2 virus (COVID-19)
FI20215186A1 (en) 2021-02-19 2022-08-20 Rebio Tech Oy Compositions for ophthalmic treatment
CA3208006A1 (en) 2021-03-17 2022-09-22 Avia MERENLENDER WAGNER Long acting injectable formulation comprising risperidone and biodegradable polymers
CA3217538A1 (en) * 2021-04-30 2022-11-03 Medincell Sa New formulation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
KR0180334B1 (ko) * 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
FR2741628B1 (fr) 1995-11-29 1998-02-06 Centre Nat Rech Scient Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
CN100408099C (zh) * 2000-11-09 2008-08-06 阿斯特拉曾尼卡有限公司 含有嵌段共聚物的口服药物组合物
KR100446101B1 (ko) * 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
DE60220519T2 (de) 2001-04-20 2007-09-27 The University Of British Columbia, Vancouver Mizellares arzneistoffverabreichungssystem für hydrophobe arzneistoffe
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
DE602004007802T2 (de) * 2003-06-26 2008-04-17 Mediolanum Pharmaceuticals Ltd. Subcutane implantate mit begrenzter initialer wirkstoff-freisetzung und deren anschliessende lineare veränderliche verlängerte freisetzung
US20050112170A1 (en) 2003-11-20 2005-05-26 Hossainy Syed F. Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same
CA2618404A1 (en) * 2005-08-04 2007-02-15 Angiotech International Ag Block copolymer compositions and uses thereof
CN101273963A (zh) * 2007-11-22 2008-10-01 山东蓝金生物工程有限公司 一种含激素类抗癌药的温控缓释注射剂
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
KR20110091515A (ko) * 2008-11-21 2011-08-11 주식회사 삼양사 내성암 치료용 고분자 미셀 조성물 및 그 제조방법
CN101810560B (zh) * 2009-02-20 2013-07-10 北京大学 环孢a聚合物胶束组合物
EP3586825B1 (en) * 2010-12-29 2023-01-18 Medincell S.A. Biodegradable drug delivery compositions

Also Published As

Publication number Publication date
MX2014015902A (es) 2015-07-17
WO2014001905A1 (en) 2014-01-03
CL2014003531A1 (es) 2015-08-28
CN104582733B (zh) 2017-07-04
IL236472A0 (en) 2015-02-26
CA2877083A1 (en) 2014-01-02
UA113549C2 (xx) 2017-02-10
IN2014DN11063A (ru) 2015-09-25
BR112014031773B1 (pt) 2020-10-13
JP6134788B2 (ja) 2017-05-24
KR102189442B1 (ko) 2020-12-11
AU2013282891A2 (en) 2015-02-05
ZA201409291B (en) 2017-05-31
ES2938586T3 (es) 2023-04-12
TN2014000520A1 (en) 2016-03-30
CO7160098A2 (es) 2015-01-15
MX353280B (es) 2018-01-05
MA37809B1 (fr) 2018-12-31
CA2877083C (en) 2020-10-06
EP2866837A1 (en) 2015-05-06
US20220354956A1 (en) 2022-11-10
CN104582733A (zh) 2015-04-29
MA37809A1 (fr) 2017-07-31
US20150150987A1 (en) 2015-06-04
SG11201408658PA (en) 2015-02-27
JP2015522001A (ja) 2015-08-03
US20200085958A1 (en) 2020-03-19
EP2866837B1 (en) 2022-12-14
CU20140148A7 (es) 2015-03-30
BR112014031773A2 (pt) 2017-06-27
AU2013282891B2 (en) 2018-04-12
CR20140581A (es) 2015-02-06
EA031522B1 (ru) 2019-01-31
AU2013282891A1 (en) 2015-01-22
CU24287B1 (es) 2017-12-08
IL236472B (en) 2020-02-27
WO2014001904A1 (en) 2014-01-03
KR20150027265A (ko) 2015-03-11
US20210008216A1 (en) 2021-01-14
US20190160171A1 (en) 2019-05-30
HK1208374A1 (en) 2016-03-04

Similar Documents

Publication Publication Date Title
EA201492172A1 (ru) Биоразлагаемая композиция для доставки гидрофобных лекарственных средств
EA201390783A1 (ru) Биоразлагаемые композиции для доставки лекарственных средств
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
TR201909461T4 (tr) Si̇stemi̇k olarak etki̇ eden akti̇f maddeleri̇ i̇çeren parazi̇ti̇si̇dal oral veteri̇nerli̇ğe ai̇t bi̇leşi̇mler, bunlarin yöntemleri̇ ve kullanimlari
BR112015018087A8 (pt) composto, composição farmacêutica e uso
EA201390662A1 (ru) Фармацевтическая композиция, содержащая дутастерид
WO2012075362A3 (en) Chemokine cxcr4 receptor modulators and used related thereto
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
MD20150053A2 (ru) Продукт со-микронизации, включающий ацетат улипристала
EA201291104A1 (ru) Пероральные лекарственные формы бендамустина
WO2012147101A3 (en) Pharmaceutical compositions of raltegravir, methods of preparation and use thereof
EA201390646A1 (ru) Фармацевтические композиции
TR201803451T4 (tr) Olmesartan formülasyonlari.
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
EA201170950A1 (ru) Новая комбинация активных ингредиентов, содержащая нестероидное противовоспалительное лекарственное средство и производное колхикозида
UA97076C2 (ru) Мазь противовоспалительная на основе сульфаниламида
TR201005911A2 (tr) Geliştirilmiş dissolüsyon profiline sahip bir ilaç formülasyonu.
TR201203083A2 (tr) Sefdinir ve klavulanik asit içeren farmasötik dozaj formu.
TR201203086A2 (tr) Sefiksim ve klavulanik asit içeren farmasötik dozaj formu.
TR201203084A2 (tr) Sefditoren pivoksil ve klavulanik asit içeren formülasyonlar.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG TJ TM